Syndax Pharmaceuticals (NASDAQ:SNDX) CFO Keith Goldan Sells 2,082 Shares of Stock

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) CFO Keith Goldan sold 2,082 shares of the company’s stock in a transaction dated Friday, February 6th. The shares were sold at an average price of $20.62, for a total transaction of $42,930.84. Following the transaction, the chief financial officer owned 143,839 shares in the company, valued at approximately $2,965,960.18. The trade was a 1.43% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

Syndax Pharmaceuticals Price Performance

Shares of SNDX stock opened at $21.01 on Friday. The firm’s 50 day moving average price is $20.67 and its two-hundred day moving average price is $16.97. The company has a debt-to-equity ratio of 2.78, a quick ratio of 4.42 and a current ratio of 4.64. Syndax Pharmaceuticals, Inc. has a 52-week low of $8.58 and a 52-week high of $22.73. The stock has a market cap of $1.83 billion, a PE ratio of -5.82 and a beta of 0.46.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in SNDX. Phoenix Financial Ltd. acquired a new position in Syndax Pharmaceuticals during the second quarter worth $701,000. Sector Gamma AS bought a new stake in Syndax Pharmaceuticals during the 3rd quarter worth about $3,243,000. Franklin Resources Inc. boosted its stake in shares of Syndax Pharmaceuticals by 14.5% during the 2nd quarter. Franklin Resources Inc. now owns 2,359,677 shares of the company’s stock worth $22,098,000 after buying an additional 298,272 shares during the last quarter. Aberdeen Group plc grew its holdings in shares of Syndax Pharmaceuticals by 129.1% in the 2nd quarter. Aberdeen Group plc now owns 303,426 shares of the company’s stock valued at $2,842,000 after acquiring an additional 170,993 shares in the last quarter. Finally, Schroder Investment Management Group increased its position in shares of Syndax Pharmaceuticals by 112.2% in the second quarter. Schroder Investment Management Group now owns 122,163 shares of the company’s stock valued at $1,144,000 after acquiring an additional 64,598 shares during the last quarter.

Wall Street Analyst Weigh In

Several research firms have weighed in on SNDX. UBS Group increased their target price on Syndax Pharmaceuticals from $35.00 to $38.00 and gave the company a “buy” rating in a research note on Tuesday, November 4th. Barclays lifted their price objective on shares of Syndax Pharmaceuticals from $22.00 to $35.00 and gave the stock an “overweight” rating in a research note on Monday, November 24th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Syndax Pharmaceuticals in a research note on Monday, December 29th. BTIG Research reiterated a “buy” rating and issued a $56.00 target price on shares of Syndax Pharmaceuticals in a report on Tuesday, December 9th. Finally, HC Wainwright reissued a “buy” rating and issued a $40.00 price target on shares of Syndax Pharmaceuticals in a report on Monday, October 27th. One research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $37.20.

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for the treatment of cancer. Headquartered in Waltham, Massachusetts, the company focuses on small-molecule inhibitors that target key epigenetic and protein interaction pathways. Syndax’s research platform aims to enhance the effectiveness of existing therapies and address high unmet medical needs in oncology.

The company’s lead investigational candidate, entinostat, is a selective class I histone deacetylase (HDAC) inhibitor being evaluated for multiple solid tumor and hematologic indications.